Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy

To the authors' knowledge, there is a scarcity of accurate data regarding the feasibility of standard chemotherapy with procarbazine, lomustine, and vincristine (PCV) in a homogeneous series of patients with primary anaplastic oligodendroglioma (AO) and oligoastrocytoma (AOA) that was recurrent after surgery and standard radiotherapy. The aim of the current study was to evaluate the overall response rate, toxicity, and time to progression (TTP) with the use of standard PCV in this setting.

[1]  Jeffrey C. Allen,et al.  Dose-intensive, Time-compressed Procarbazine, CCNU, Vincristine (PCV) with Peripheral Blood Stem Cell Support and Concurrent Radiation in Patients with Newly Diagnosed High-grade Gliomas , 1999, Journal of Neuro-Oncology.

[2]  A. Brandes,et al.  Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Prados,et al.  Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  W. Yung,et al.  Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. , 2002, International journal of radiation oncology, biology, physics.

[6]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[7]  M. Prados,et al.  Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  S. Rosenfeld,et al.  Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. , 2000, Neuro-oncology.

[9]  A. Twijnstra,et al.  Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.

[10]  A. Brandes,et al.  Clinical, pathological and therapeutic aspects of oligodendroglioma. , 1998, Cancer treatment reviews.

[11]  D. Louis,et al.  Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. , 1996, Journal of neurosurgery.

[12]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Bruner,et al.  The treatment of anaplastic oligodendrogliomas and mixed gliomas. , 1993, Neurosurgery.

[14]  P. Duffey,et al.  The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[17]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[18]  Hryniuk Wm.  Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.

[19]  J. Goldie,et al.  Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987, Seminars in oncology.

[20]  W. Hryniuk.  Average relative dose intensity and the impact on design of clinical trials. , 1987, Seminars in oncology.

[21]  M. Palmer,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.

[22]  V. Levin,et al.  Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. , 1980, Cancer treatment reports.

[23]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[24]  Z. Szentirmay,et al.  Quantitative cytochemical investigations on Ehrlich ascites tumour cells treated with vincristine. IV. Interference microscopic investigations. , 1973, Neoplasma.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  D.,et al.  Regression Models and Life-Tables , 2022 .